LOS ANGELES–(BUSINESS WIRE)–Today AIDS Healthcare Foundation President Michael Weinstein issued the following statement on findings recently published in the Antimicrobial Agents and Chemotherapy report that scientists from the Oak Crest Institute of Science have created the first subdermal implant that delivers antiretroviral drugs for up to 40 days to prevent or treat HIV:

“Numerous medical studies and our years of treating people living with HIV all over the world have proven to us that one of the most significant challenges in suppressing the virus is getting patients to take their medications every single day. From the beginning of the debate on pre-exposure prophylaxis as a public health strategy, AHF has said that we would support a vaccine or implant that reduces the human tendency to skip doses. While patient studies, federal approval, and information on pricing and availability is still needed at this early stage, the news that scientists have created the first implant to deliver HIV medications for prevention or treatment is a potential medical breakthrough that AHF wholeheartedly welcomes. We’ll be closely monitoring the next steps following these promising preliminary studies.”

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 415,000 individuals in 36 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare

Source: Business Wire Health